Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
a core business (ex-Jakafi) that was ~$1.2B in 2025 and management forecasting a 15–20% five-year CAGR toward $3–4B by 2030, supported by four near-term launches including Jakafi XR, frontline Monjuvi (DLBCL), Opzelura for moderate atopic dermatitis in Europe, and povorcitinib. INCB0989 (mCALR antibody) advancement: Early data showed high complete hematologic responses in ET and meaningful anemia improvements in 50% of MF patients, and Incyte plans at least two phase III studies this year with a subcutaneous formulation entering the clinic and intended for pivotal trials. Pivotal pipeline momentum across oncology and immunology: Incyte is progressing a JAK2 V617F program with new formulation and year-end data expected, plans a regulatory submission for Monjuvi in frontline DLBCL (submission H1 2026; possible approval late-2026/early-2027), reported ~15% responses for its TGFßR2xPD-1 bispecific in MSS colorectal (phase III started), and is moving a KRAS G12D pancreatic program towa
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.MarketBeat
- Incyte Announces Executive Leadership AppointmentsBusiness Wire
- Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.MarketBeat
- Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- Incyte: An Undervalued Healthcare Gem [Seeking Alpha]Seeking Alpha
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 3/26/26 - Form 8-K
- 3/19/26 - Form 4
- 3/17/26 - Form 144
- INCY's page on the SEC website